Chicago Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.1M | Sell |
40,087
-2,939
| -7% | -$632K | 0.24% | 63 |
|
|
2026
Q1 | $9.36M | Sell |
43,026
-1,086
| -2% | -$241K | 0.25% | 60 |
|
|
2025
Q4 | $10.1M | Buy |
44,112
+1,662
| +4% | +$379K | 0.25% | 64 |
|
|
2025
Q3 | $9.83M | Sell |
42,450
-110
| -0.3% | -$22.4K | 0.24% | 65 |
|
|
2025
Q2 | $7.9M | Buy |
42,560
+57
| +0.1% | +$10.6K | 0.2% | 70 |
|
|
2025
Q1 | $8.91M | Sell |
42,503
-10,500
| -20% | -$2.04M | 0.25% | 63 |
|
|
2024
Q4 | $9.42M | Buy |
53,003
+307
| +0.6% | +$56.4K | 0.25% | 67 |
|
|
2024
Q3 | $10.4M | Sell |
52,696
-787
| -1% | -$147K | 0.29% | 63 |
|
|
2024
Q2 | $9.17M | Sell |
53,483
-344
| -0.6% | -$57K | 0.27% | 64 |
|
|
2024
Q1 | $9.8M | Sell |
53,827
-592
| -1% | -$102K | 0.3% | 58 |
|
|
2023
Q4 | $8.43M | Buy |
54,419
+11,405
| +27% | +$1.66M | 0.3% | 54 |
|
|
2023
Q3 | $6.41M | Buy |
43,014
+200
| +0.5% | +$29.4K | 0.3% | 52 |
|
|
2023
Q2 | $5.77M | Sell |
42,814
-605
| -1% | -$88.7K | 0.26% | 51 |
|
|
2023
Q1 | $6.92M | Hold |
43,419
| – | – | 0.34% | 52 |
|
|
2022
Q4 | $7.02M | Sell |
43,419
-85
| -0.2% | -$13K | 0.39% | 53 |
|
|
2022
Q3 | $5.84M | Buy |
43,504
+15
| +0% | +$2.15K | 0.34% | 54 |
|
|
2022
Q2 | $6.66M | Buy |
43,489
+1,400
| +3% | +$214K | 0.37% | 52 |
|
|
2022
Q1 | $6.82M | Buy |
42,089
+1,380
| +3% | +$200K | 0.29% | 56 |
|
|
2021
Q4 | $5.51M | Buy |
40,709
+612
| +2% | +$72.3K | 0.21% | 60 |
|
|
2021
Q3 | $4.33M | Sell |
40,097
-40
| -0.1% | -$4.57K | 0.16% | 62 |
|
|
2021
Q2 | $4.52M | Buy |
40,137
+427
| +1% | +$48.1K | 0.18% | 60 |
|
|
2021
Q1 | $4.3M | Buy |
39,710
+432
| +1% | +$46.2K | 0.18% | 58 |
|
|
2020
Q4 | $4.21M | Buy |
39,278
+91
| +0.2% | +$8.74K | 0.19% | 59 |
|
|
2020
Q3 | $3.43M | Buy |
39,187
+25
| +0.1% | +$2.35K | 0.18% | 63 |
|
|
2020
Q2 | $3.85M | Buy |
39,162
+8,961
| +30% | +$789K | 0.22% | 57 |
|
|
2020
Q1 | $2.3M | Hold |
30,201
| – | – | 0.19% | 66 |
|
|
2019
Q4 | $2.67M | Hold |
30,201
| – | – | 0.16% | 71 |
|
|
2019
Q3 | $2.29M | Buy |
30,201
+350
| +1% | +$24K | 0.15% | 72 |
|
|
2019
Q2 | $2.17M | Buy |
29,851
+2,150
| +8% | +$169K | 0.14% | 75 |
|
|
2019
Q1 | $2.23M | Buy |
27,701
+480
| +2% | +$39.3K | 0.15% | 73 |
|
|
2018
Q4 | $2.51M | Buy |
27,221
+3,953
| +17% | +$348K | 0.2% | 63 |
|
|
2018
Q3 | $2.2M | Buy |
23,268
+87
| +0.4% | +$8.25K | 0.15% | 65 |
|
|
2018
Q2 | $2.15M | Buy |
23,181
+2,646
| +13% | +$258K | 0.17% | 66 |
|
|
2018
Q1 | $1.94M | Buy |
+20,535
| New | +$2.26M | 0.26% | 58 |
|
Other funds holding ABBV
Chicago Capital's ABBV Position: Q2 2026 in Review
Chicago Capital reduced its AbbVie (ABBV) stake by 6.8% in Q2 2026, selling an estimated $632K and leaving 40,087 shares worth $10.1M. The position accounts for 0.24% of the portfolio, ranked #63.
Chicago Capital first reported a position in ABBV in Q1 2018 and has held it in 34 quarters since. The position peaked at $10.4M in Q3 2024. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Chicago Capital held 40,087 shares of AbbVie worth $10.1M as of Q2 2026.
- Chicago Capital sold 2,939 AbbVie shares in Q2 2026, an estimated $632K.
- AbbVie made up 0.24% of Chicago Capital's portfolio in Q2 2026, its #63 holding.
- Chicago Capital first reported a position in AbbVie in Q1 2018 and has held it in 34 quarters since.
- Chicago Capital's AbbVie position peaked at $10.4M in Q3 2024.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Chicago Capital's 13F filing for Q2 2026, filed 28 Jul 2026.